(Press-News.org) Researchers at Women & Infants Hospital of Rhode Island have developed a biologic drug that would prevent the production of a protein known to allow ovarian cancer cells to grow aggressively while being resistant to chemotherapy. This would improve treatment and survival rates for some women.
The work coming out of the molecular therapeutic laboratory directed by Richard G. Moore, MD, entitled "HE4 (WFDC2) gene overexpression promotes ovarian tumor growth" was recently published in the international science journal Scientific Reports, a Nature publishing group.
"We have known that the protein HE4 is present in women who have ovarian cancer," says Moore, who created the Risk of Ovarian Malignancy Algorithm (ROMA) to determine if a pelvic mass is cancerous based on the levels of HE4 and another protein. "What no one knew was why the protein is there or what activates it."
The WFCD2 gene produces a "messenger RNA" that encodes for the HE4 protein, not only imparting an aggressiveness to the tumor, enabling it to grow quickly, but also conveying a resistance to chemotherapy drugs used to treat the tumor.
"It plays a part in allowing the cancer to grow without restriction," Moore says. "We have determined that HE4 plays a part in allowing ovarian cells to become cancer cells, giving them the ability to grow and resist chemo."
Once they identified the function of the protein, Moore's research team was able to design a biologic drug that can prevent the messenger RNA gene from creating HE4. The novel biologic has been tested in cell and animal models, and the results are that the cancer does not grow as aggressively and responds to chemotherapy.
"We would give this biologic – which has minimal side effects – to any patient we identify through a blood test as producing HE4," he says, adding that oncologists have recognized that women with high levels of HE4 do not respond to treatment and their survival rates are lower. "This would be an individualized treatment that could increase survival rates of some women with ovarian cancer."
Moore and his team will continue testing the biologic drug, preparing for clinical trials in humans.
"This is a tremendous discovery and could mean the difference between life or death for some women with ovarian cancer," says Maureen G. Phipps, MD, MPH, chief of obstetrics and gynecology at Women & Infants. "Dr. Moore's research is ground-breaking in the area of ovarian cancer, and it's all happening in his laboratory in the Knowledge District of Providence."
INFORMATION:
About Women & Infants Hospital
Women & Infants Hospital of Rhode Island, a Care New England hospital, is one of the nation's leading specialty hospitals for women and newborns. The primary teaching affiliate of The Warren Alpert Medical School of Brown University for obstetrics, gynecology and newborn pediatrics, as well as a number of specialized programs in women's medicine, Women & Infants is the eighth largest stand-alone obstetrical service in the country with nearly 8,400 deliveries per year. In 2009, Women & Infants opened the country's largest, single-family room neonatal intensive care unit.
New England's premier hospital for women and newborns, Women & Infants and Brown offer fellowship programs in gynecologic oncology, maternal-fetal medicine, urogynecology and reconstructive pelvic surgery, women's mental health, neonatal-perinatal medicine, pediatric and perinatal pathology, gynecologic pathology and cytopathology, and reproductive endocrinology and infertility. It is home to the nation's only mother-baby perinatal psychiatric partial hospital, as well as the nation's only fellowship program in obstetric medicine.
Women & Infants has been designated as a Breast Center of Excellence from the American College of Radiography; a Center for In Vitro Maturation Excellence by SAGE In Vitro Fertilization; a Center of Biomedical Research Excellence by the National Institutes of Health; and a Neonatal Resource Services Center of Excellence. It is one of the largest and most prestigious research facilities in high risk and normal obstetrics, gynecology and newborn pediatrics in the nation, and is a member of the National Cancer Institute's Gynecologic Oncology Group and the National Institutes of Health's Pelvic Floor Disorders Network.
Targeted treatment for ovarian cancer discovered
2014-02-19
ELSE PRESS RELEASES FROM THIS DATE:
UNH research: Most of us have made best memories by age 25
2014-02-19
DURHAM, N.H. – By the time most people are 25, they have made the most important memories of their lives, according to new research from the University of New Hampshire.
Researchers at UNH have found that when older adults were asked to tell their life stories, they overwhelmingly highlighted the central influence of life transitions in their memories. Many of these transitions, such as marriage and having children, occurred early in life.
"When people look back over their lives and recount their most important memories, most divide their life stories into chapters ...
How stick insects honed friction to grip without sticking
2014-02-19
When they're not hanging upside down, stick insects don't need to stick. In fact, when moving upright, sticking would be a hindrance: so much extra effort required to 'unstick' again with every step.
Latest research from Cambridge's Department of Zoology shows that stick insects have specialised pads on their legs designed to produce large amounts of friction with very little pressure. When upright, stick insects aren't sticking at all, but harnessing powerful friction to ensure they grip firmly without the need to unglue themselves from the ground when they move. ...
Addicted to tanning?
2014-02-19
BOWLING GREEN, O.—They keep tanning, even after turning a deep brown and experiencing some of the negative consequences. Skin cancer is among the most common, preventable types of the disease, yet many continue to tan to excess.
Research from Lisham Ashrafioun, a Bowling Green State University Ph.D. student in psychology, and Dr. Erin Bonar, an assistant professor of psychiatry at the University of Michigan Addiction Research Center and a BGSU alumna, shows that some who engage in excessive tanning may also be suffering from obsessive-compulsive (OCD) and body dysmorphic ...
A forgotten model of the universe
2014-02-19
A paper published in EPJ H provides the first English translation and an analysis of one of Albert Einstein's little-known papers, "On the cosmological problem of the general theory of relativity." Published in 1931, it features a forgotten model of the universe, while refuting Einstein's own earlier static model of 1917. In this paper, Einstein introduces a cosmic model in which the universe undergoes an expansion followed by a contraction. This interpretation contrasts with the monotonically expanding universe of the widely known Einstein-de Sitter model of 1932.
The ...
Family problems experienced in childhood and adolescence affect brain development
2014-02-19
New research has revealed that exposure to common family problems during childhood and early adolescence affects brain development, which could lead to mental health issues in later life.
The study led by Dr Nicholas Walsh, lecturer in developmental psychology at the University of East Anglia (UEA), used brain imaging technology to scan teenagers aged 17-19. It found that those who experienced mild to moderate family difficulties between birth and 11 years of age had developed a smaller cerebellum, an area of the brain associated with skill learning, stress regulation ...
Minor added benefit of indacaterol/glycopyrronium in COPD
2014-02-19
The drug combination indacaterol/glycopyrronium (trade name: Ultibro Breezhaler, Xoterna Breezhaler) has been approved since September 2013 for adults with chronic obstructive pulmonary disease (COPD). In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products (AMNOG), the German Institute for Quality and Efficiency in Health Care (IQWiG) examined whether this drug combination offers an added benefit over the appropriate comparator therapy.
According to the findings, the drug combination is better at relieving breathing difficulties ...
Afatinib: Added benefit depends on mutation status
2014-02-19
Afatinib (trade name: GIOTRIF) has been approved in Germany since September 2013 for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGF receptor mutations who have not been treated with an EGF receptor tyrosine-kinase inhibitor (EGFR TKI). In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products (AMNOG), the German Institute for Quality and Efficiency in Health Care (IQWiG) examined whether this new drug offers an added benefit over the appropriate comparator ...
Scientists identify 'long distance scanner' for DNA damage
2014-02-19
Scientists at the University of Bristol have discovered that a mechanism for preventing mutation within important genes involves long distance scanning of DNA by a molecular motor protein.
The results, published in the Proceedings of the National Academy of Sciences (PNAS), show that the method for detecting DNA damage within active genes is more sophisticated than previously thought.
The research team hope that the mechanistic insights provided by this study will help to explain the complicated genome-wide patterns of mutation that underlie the evolution of new species, ...
The nose knows in asthma
2014-02-19
It has become increasingly clear in recent years that asthma comes in several variations, with different causes, different pathologies and different responses to therapy. These subtypes of asthma can be identified by knowing which genes are expressed at higher and lower levels in patients' airways. That information can, in turn, help guide personalized treatment to more effectively manage asthma and inspire research to better understand, manage, and possibly prevent asthma.
The difficulty is that tissue samples necessary for this kind of genetic profiling are currently ...
Diamonds in the tail of the scorpion
2014-02-19
Messier 7, also known as NGC 6475, is a brilliant cluster of about 100 stars located some 800 light-years from Earth. In this new picture from the Wide Field Imager on the MPG/ESO 2.2-metre telescope it stands out against a very rich background of hundreds of thousands of fainter stars, in the direction of the centre of the Milky Way.
At about 200 million years old, Messier 7 is a typical middle-aged open cluster, spanning a region of space about 25 light-years across. As they age, the brightest stars in the picture — a population of up to a tenth of the total stars in ...